Peptides for Blood Pressure: Research on Cardiovascular Peptides

Key Takeaways

• What this covers: Three distinct peptide categories relevant to blood pressure: food-derived ACE-inhibitory bioactives, endogenous natriuretic peptides, and FDA-approved cardiovascular therapeutics (including GLP-1 drugs).
• Regulatory status: As of April 2026, FDA-approved drugs that have demonstrated blood pressure effects in clinical trials include peptide drugs (GLP-1 receptor agonists: semaglutide, tirzepatide — approved for type 2 diabetes and chronic weight management; hypertension is not an approved indication) and small-molecule drugs that potentiate endogenous natriuretic peptide signaling (sacubitril/valsartan — a neprilysin inhibitor combined with an ARB, approved for heart failure management). Food-derived bioactive peptides are dietary components, not drugs.
• Evidence stage: Therapeutic peptides have robust Phase 3 trial data. Food-derived ACE-inhibitory peptides have in vitro and limited human evidence, with oral bioavailability as a persistent limitation.
• Primary distinction: The mechanism of ACE inhibition is shared between food peptides and prescription ACE-inhibitor drugs, but the evidence quality, bioavailability, and clinical utility are fundamentally different between these categories.

What Is the Peptide-Blood Pressure Connection?

Blood pressure is regulated through multiple peptide systems operating in parallel. The renin-angiotensin-aldosterone system (RAAS) is among the most pharmacologically targeted: angiotensin II, a short peptide produced through ACE-mediated cleavage of angiotensin I, is one of the most potent vasoconstrictors in the body. The natriuretic peptide system operates as a counterbalance: ANP and BNP, produced by cardiac tissue under pressure overload, promote vasodilation and sodium excretion. GLP-1 and related incretin peptides have vasoactive properties through distinct receptor pathways.

Guo and colleagues, in a 2025 comprehensive review in Food Chemistry, noted that food-derived peptides operate on at least three of these pathways: ACE inhibition, ACE2 pathway activation, and renin inhibition, with the relative importance of each depending on the peptide sequence and physiological context. Ichim and colleagues, reviewing antihypertensive peptides in Molecular Nutrition and Food Research in 2024, provided a comprehensive synthesis of food-derived bioactive peptides in hypertension, including both ACE inhibition and the ACE2/Ang(1-7)/MasR axis.

What Is an ACE-Inhibitory Peptide?

An ACE-inhibitory peptide is a short amino acid sequence that occupies the active site of angiotensin-converting enzyme and blocks its ability to convert angiotensin I (a physiologically inert decapeptide) to angiotensin II (a potent vasoconstrictor). The downstream effect is reduced vascular resistance and lower blood pressure. This is the same mechanism exploited by widely used prescription ACE-inhibitor drugs — the difference is that pharmaceutical ACE inhibitors are engineered small molecules designed for tight ACE binding and defined bioavailability, while food-derived peptides are naturally occurring fragments released from dietary proteins during digestion or fermentation.

Hong and colleagues, writing in Peptides in 2008, reviewed the antihypertensive effect of food peptides as a novel alternative to drugs, providing an early foundational bridge between food peptide science and pharmaceutical antihypertensive strategies. Murray and colleagues, in a 2007 review in Current Pharmaceutical Design, covered the biochemistry, bioavailability, and structure-activity relationships of ACE-inhibitory peptides from food proteins in detail, establishing the pharmacological framework that subsequent research has refined. Saleh and colleagues, in a comprehensive 2016 review in Critical Reviews in Food Science and Nutrition, catalogued the antihypertensive activity of food protein hydrolysates and peptides across the full range of characterized sources.

Where ACE-Inhibitory Peptides Come From

The three main source categories are dairy, marine, and plant proteins, each with a distinct evidence base and distinct peptide profiles.

Dairy-derived peptides

Dairy proteins — particularly whey and casein — are among the most extensively studied sources of ACE-inhibitory peptides. FitzGerald and colleagues, in a 1999 paper in Nahrung, identified lactokinins as milk-based antihypertensive peptides. The two most studied peptides from casein hydrolysates — tripeptides IPP (isoleucyl-prolyl-proline) and VPP (valyl-prolyl-proline) — have been tested in human studies with inconsistent blood pressure effects across trials, with meta-analyses reporting small reductions in some populations and no effect in others. Shukla and colleagues, in a 2022 review in Protein and Peptide Letters, catalogued current trends in food-derived antihypertensive peptides, identifying dairy, soy, and fish as the best-characterized sources. Martin and colleagues, reviewing human and animal study outcomes in Critical Reviews in Food Science and Nutrition in 2019, found that natural food-protein peptides and blood pressure across multiple species, though human effect sizes were typically small and variable.

Marine-derived peptides

Fish proteins yield ACE-inhibitory peptides on hydrolysis, and the marine category has expanded substantially in recent years. Abachi and colleagues, in a 2019 review in Marine Drugs, identified antihypertensive peptides from fish. Kim and colleagues, in a 2012 review in Advances in Food and Nutrition Research, provided an earlier assessment of marine fish-derived bioactive peptides as potential antihypertensives, documenting the diversity of fish species and hydrolysis conditions producing active peptides.

Plant-derived peptides

Plant proteins from soy, pea, flaxseed, hemp, and diverse seeds produce ACE-inhibitory fragments on proteolytic hydrolysis. Nwachukwu and colleagues, in a 2014 study in the International Journal of Molecular Sciences, characterized flaxseed protein antihypertensive peptide fractions, demonstrating that plant seed proteins can produce potent ACE-inhibitory sequences. Elbira and colleagues, in a 2025 study in Foods, demonstrated that pre-hydrolyzed pea protein bioactive peptides including antihypertensives, showing that processing method affects peptide yield. More recently, Hung and colleagues, publishing in Plant Foods for Human Nutrition in 2025, identified novel antihypertensive tetrapeptides from Perilla frutescens seeds evaluated for antihypertensive activity in research studies. Amigo-Benavent and colleagues, in a 2026 paper in Food and Function, identified hemp-derived dipeptidyl peptidase inhibitory peptides — a mechanistically distinct pathway (dipeptidyl peptidase-4 inhibition is associated with glucose regulation rather than blood pressure). The hemp research base includes both glucose-pathway and blood-pressure-pathway bioactive peptides; the DPP-inhibitory finding is a glucose-pathway result.

The Bioavailability Problem

Understanding whether food-derived ACE-inhibitory peptides actually reach and inhibit ACE in vascular tissue after oral ingestion is the central unresolved question in this field. Vermeirssen and colleagues, in a 2004 study in the British Journal of Nutrition, directly examined this limitation: bioavailability of ACE-inhibitory peptides — whether they survive digestion and reach circulation — was found to vary substantially by sequence and showed significant degradation by gastrointestinal proteases [human observational study]. Aluko, in a 2019 review in the Journal of Food Biochemistry, noted that renin-inhibitory peptides from food proteins — a mechanistically distinct antihypertensive pathway — face similar bioavailability constraints.

The practical implication: in vitro ACE inhibition data (the predominant type in the literature) does not confirm that a peptide will lower blood pressure in humans. The compound must survive gastric acid, brush-border enzymes, and intestinal wall metabolism, then reach systemic circulation in sufficient concentration to inhibit peripheral ACE. Most identified bioactive peptides do not meet this threshold in vivo. The human studies that do show blood pressure effects typically use highly concentrated, bioavailability-optimized formulations at doses that would not be achieved through normal dietary intake.

Endogenous Natriuretic Peptides and Blood Pressure

The natriuretic peptide system is the body's own antihypertensive peptide response to elevated cardiac pressure. Understanding it provides context for clinical biomarkers and pharmaceutical development in this area.

ANP and BNP

Atrial natriuretic peptide (ANP) is produced primarily in cardiac atria; B-type natriuretic peptide (BNP) originates mainly in ventricular myocardium. Both are released in response to cardiac wall stretch from volume overload or pressure elevation. Goetze and colleagues, reviewing natriuretic peptides in Nature Reviews Cardiology in 2020, described how natriuretic peptides ANP and BNP regulate blood pressure and fluid homeostasis through simultaneous natriuresis (promoting renal sodium and water excretion), vasodilation (relaxing smooth muscle through cGMP signaling), and RAAS suppression. Kuwahara, reviewing the natriuretic peptide system in Pharmacology and Therapeutics in 2021, characterized BNP both as a BNP as blood pressure regulator and biomarker, explaining why clinically elevated BNP signals that the heart is under physiological stress.

An exogenous recombinant BNP (nesiritide, Natrecor) received FDA approval in 2001 for acutely decompensated heart failure, but its clinical use declined substantially after the ASCEND-HF trial (O'Connor and colleagues, NEJM 2011) did not demonstrate meaningful clinical benefit over standard care. This history is part of why current pharmacological strategy emphasizes potentiating endogenous natriuretic peptides (via neprilysin inhibition) rather than administering exogenous peptide.

C-type natriuretic peptide (CNP)

CNP is structurally related to ANP and BNP but is produced predominantly in vascular endothelium and the central nervous system rather than cardiac tissue. It acts primarily as a local paracrine vasodilator rather than a systemic hormone. Dickinson and colleagues, in a 2024 review in Pharmacology and Therapeutics, described C-type natriuretic peptide and vasodilation, positioning CNP as a distinct pathway from cardiac-derived natriuretic peptides with specific relevance to vascular biology. Sangaralingham and colleagues, in a 2023 review in Cardiovascular Research, examined natriuretic peptide pathways and their therapeutic possibilities for heart failure and blood pressure management, noting that CNP-based therapeutics represent a development direction distinct from augmenting the ANP/BNP system.

GLP-1 Receptor Agonists: Cardiovascular Outcomes in Approved Indications

Semaglutide received expanded FDA approval in 2024 to reduce the risk of major adverse cardiovascular events in adults with cardiovascular disease and overweight or obesity; blood pressure management itself is not an FDA-approved indication. GLP-1 receptor agonists have a robust clinical evidence base that includes documented blood pressure effects observed as secondary endpoints in major cardiovascular outcome trials. The mechanism of GLP-1 RA blood pressure effects is likely multifactorial. Weight reduction from GLP-1 therapy independently lowers blood pressure, and this is the best-established contributor. Proposed direct vascular effects through GLP-1 receptors expressed in vascular endothelium and in the kidney have been described mechanistically but are not consistently replicated across clinical studies. Natriuresis has been observed in some pharmacological studies but is not an established clinical effect at therapeutic dosing. Blood pressure lowering in GLP-1 RA trials is best characterized as a secondary consequence of weight-driven cardiometabolic improvement, with additional contributing mechanisms under continued investigation.

Liu and colleagues, in a 2025 review in Drug Design, Development and Therapy, covered the clinical applications of GLP-1 and GIP agonists across their approved indications (type 2 diabetes, chronic weight management) and related cardiovascular outcome trial findings, noting that blood pressure lowering was a consistent secondary finding across the major cardiovascular outcome trials. Petsas and colleagues, in a 2025 review in Molecules, positioned protein-ligand interactions in cardiometabolic drug targets — including GLP-1 pathway agents — within the cardiovascular drug development pipeline. The established finding from the SELECT trial is that semaglutide reduced major adverse cardiovascular events by approximately 20% over 33 months in a non-diabetic cardiovascular risk population; blood pressure reduction contributed to but did not fully explain this benefit. Blood pressure reduction was observed as a secondary endpoint within the SELECT trial population and in the SURPASS tirzepatide trial program for type 2 diabetes. GLP-1 receptor agonists are not FDA-approved for hypertension management, and any BP-related use is off-label.

What the Research Shows: Evidence by Level

As of April 2026, the evidence for peptides and blood pressure spans from highly validated (FDA-approved therapeutics) to suggestive but bioavailability-limited (food-derived bioactives).

• In vitro (ACE inhibition assays)
  • Volume of evidence: Extensive; hundreds of peptide sequences characterized
  • Key finding: Numerous food-derived peptides from dairy, fish, and plant proteins inhibit ACE at nanomolar to micromolar concentrations in assay systems
  • Strength of inference: Establishes ACE-binding activity; does not establish in vivo blood pressure effect
• Animal models
  • Volume of evidence: Substantial; spontaneously hypertensive rat (SHR) model used extensively
  • Key finding: Multiple food-derived peptide fractions lower systolic blood pressure in SHR models after oral administration
  • Strength of inference: Supports plausibility; SHR model does not replicate human essential hypertension pathophysiology
• Human observational and trial data
  • Volume of evidence: Limited for food-derived peptides; robust for GLP-1 drugs and natriuretic peptide therapeutics
  • Key finding: Dairy-derived IPP/VPP peptides showed modest blood pressure reductions in some human trials; GLP-1 drugs showed consistent but modest blood pressure lowering as a secondary endpoint in cardiovascular outcome trials
  • Strength of inference: Moderate for GLP-1 drugs; limited and inconsistent for food-derived peptides; highest for FDA-approved cardiovascular peptide therapeutics

How to Access Cardiovascular Peptides

Access pathways differ fundamentally by category.

FDA-approved GLP-1 receptor agonists (semaglutide, tirzepatide) require a prescription from a licensed US healthcare provider and are dispensed through licensed pharmacies. Semaglutide is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and cardiovascular risk reduction in overweight/obese adults with established cardiovascular disease (SELECT indication, approved March 2024). Tirzepatide is approved for type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and obstructive sleep apnea in adults with obesity (approved December 2024). As of April 2026, these compounds require clinical evaluation and ongoing provider supervision. Hypertension is not an approved indication for any GLP-1 receptor agonist.

Sacubitril/valsartan (Entresto), a small-molecule drug combining a neprilysin inhibitor with an ARB, potentiates endogenous natriuretic peptides indirectly by blocking their degradation. It is a prescription medication approved for heart failure management, not OTC.

Food-derived ACE-inhibitory peptides are not pharmaceutical products. They are consumed through dietary protein sources (dairy, fish, plant proteins) or as dietary supplement concentrates. Functional food and supplement products containing dairy-derived tripeptides (IPP, VPP) have been marketed internationally, including under Japan's FOSHU (Foods for Specified Health Uses) regulatory framework. In the US, such products fall under DSHEA: they are regulated as dietary supplements, cannot carry hypertension treatment claims, and FDA does not pre-approve their efficacy. Permissible framing in the US is limited to structure/function claims such as "supports healthy blood pressure already within the normal range," accompanied by the mandatory FDA disclaimer: "This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Safety Considerations

The safety profile for peptides in this context is highly dependent on category.

Known adverse effects

GLP-1 receptor agonists have a well-characterized adverse event profile from large clinical trials: nausea, vomiting, and diarrhea are the most common, occurring in 10-40% of participants depending on titration rate; pancreatitis and gallbladder disease are rare but reported adverse events; injection site reactions occur at low frequency [human RCT data from multiple trials]. Food-derived ACE-inhibitory peptides consumed in dietary quantities have no established adverse effect profile. The theoretical concern for supplement concentrates is additive hypotension in individuals already taking ACE-inhibitor or ARB medications [pharmacological reasoning].

Populations who should exercise caution

• Individuals on prescription antihypertensive medications: Adding ACE-inhibitory peptide supplements to an existing ACE-inhibitor or ARB regimen carries theoretical risk of additive blood pressure lowering, including hypotension. Discussion with a prescribing provider is appropriate.
• Individuals with history of pancreatitis or pancreatic cancer: GLP-1 receptor agonists carry an FDA class labeling on pancreatitis risk; individuals with prior pancreatitis require clinical evaluation before use.
• Individuals with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2): GLP-1 receptor agonists carry an FDA contraindication for these individuals based on thyroid C-cell tumor findings in rodent models. Prescribing is contraindicated in this population per the approved labeling.
• Individuals with severe renal impairment: Natriuretic effects of antihypertensive peptides and GLP-1 drugs may affect renal function; monitoring is appropriate.

What is not yet known

The long-term cardiovascular effects of food-derived ACE-inhibitory peptide supplementation have not been studied in prospective human trials with cardiovascular endpoints. Interaction data between food-derived ACE-inhibitory peptides and prescription antihypertensives is not established in clinical studies. Whether the ACE2/Ang(1-7)/MasR pathway activated by certain food peptides, as described by Liao and colleagues in a 2021 review in Critical Reviews in Food Science and Nutrition, ACE2/Ang(1-7)/MasR pathway as emerging target, has meaningful clinical relevance in humans at achievable dietary doses remains an open question.

Which Biomarkers Are Relevant for Cardiovascular Peptide Evaluation?

Understanding baseline cardiovascular biology provides context for evaluating any compound that acts on blood pressure regulation systems. The relevant markers span vascular, metabolic, and cardiac biology.

• Blood pressure measurement: Foundational — serial home blood pressure monitoring or clinical ambulatory blood pressure monitoring provides the primary endpoint for any blood pressure intervention. Not a laboratory biomarker but the essential measurement.
• Lipid panel (LDL, HDL, triglycerides): Elevated LDL cholesterol and triglycerides are independent cardiovascular risk factors that operate alongside blood pressure. GLP-1 therapy affects lipid parameters as well as blood pressure, making baseline values essential for interpreting compound-specific effects.
• hs-CRP: Systemic inflammatory burden as measured by high-sensitivity C-reactive protein is an established cardiovascular risk modifier. Anti-inflammatory effects of GLP-1 compounds contributed to their cardiovascular outcome trial results.
• Fasting glucose and HbA1c: Metabolic context is inseparable from cardiovascular risk. HbA1c and fasting glucose characterize insulin sensitivity and glycemic control — parameters directly targeted by GLP-1 receptor agonists.
• Homocysteine: Elevated homocysteine is associated with endothelial dysfunction and cardiovascular risk. It reflects one-carbon metabolism and methylation status rather than the RAAS or natriuretic peptide systems directly, but contributes to a complete cardiovascular risk picture.
• BNP or NT-proBNP: Circulating natriuretic peptide levels reflect cardiac wall stress. Elevated values indicate the cardiac natriuretic peptide system is under activation — clinically relevant context for anyone exploring natriuretic peptide pharmacology or evaluating cardiac status alongside blood pressure.

Establishing a baseline across these markers before initiating any antihypertensive compound — dietary, supplement, or pharmaceutical — is how you make subsequent changes interpretable. That is the foundation of Superpower's approach to preventive health: objective data first.

IMPORTANT SAFETY INFORMATION

This page covers multiple compound categories with different regulatory statuses. FDA-approved GLP-1 receptor agonists (semaglutide, tirzepatide) are prescription medications requiring clinical evaluation by a licensed healthcare provider; they are not indicated specifically for hypertension. Natriuretic peptide-potentiating pharmaceuticals (such as sacubitril/valsartan) are prescription medications for heart failure management. Food-derived ACE-inhibitory peptides are dietary components or dietary supplements regulated under DSHEA. For any such product making a structure/function claim, the mandatory FDA disclaimer applies: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease." Superpower Health connects members with licensed providers who prescribe FDA-approved GLP-1 medications (such as Ozempic, Wegovy, Mounjaro, Zepbound) where clinically appropriate. Compounded GLP-1 formulations were widely available under the FDA drug shortage exception while semaglutide (resolved early 2025) and tirzepatide (resolved late 2024) were on the FDA shortage list; post-shortage-resolution, compounded formulations of these molecules are materially restricted. See individual product pages for current availability and regulatory details. Compounded drugs are not FDA-approved; compounding is a pharmacy practice, not a product approval.

Hypertension is a medical condition requiring clinical evaluation and management. This page does not provide guidance for managing blood pressure and is not a substitute for a healthcare provider's evaluation. Do not adjust prescription antihypertensive medications based on content on this page.

Warnings for GLP-1 receptor agonists: nausea, vomiting, diarrhea (common); acute pancreatitis (rare; use caution in patients with history of pancreatitis); gallbladder disease; injection site reactions. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Individuals on prescription ACE inhibitors or ARBs should discuss any ACE-inhibitory peptide supplement with their prescribing provider before use due to potential additive blood pressure effects.

As of April 2026, no food-derived ACE-inhibitory peptide product has received FDA approval for blood pressure management. In vitro ACE inhibition data does not establish in vivo clinical efficacy. Full prescribing information for FDA-approved GLP-1 medications is available in their respective FDA-approved labeling.

Disclaimer: IMPORTANT: This article discusses multiple peptide categories with different regulatory statuses. FDA-approved GLP-1 drugs require prescription. Food-derived bioactive peptides are dietary components, not FDA-approved drugs for hypertension. This content is for educational purposes only and does not constitute medical advice.